Back to Journals » International Medical Case Reports Journal » Volume 10

The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature

Authors Bi J, Liu H, Huang Y

Received 19 March 2017

Accepted for publication 1 June 2017

Published 4 July 2017 Volume 2017:10 Pages 223—227


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Ronald Prineas

Jinling Bi, Haiyuan Liu, Yong Huang

Department of Oncology, The Second People’s Hospital of He Fei, He Fei, An Hui, People’s Republic of China

Abstract: The aim of this study was to explore the effect of apatinib in the treatment of metastatic renal cell carcinoma (mRCC) and related adverse events. A case of mRCC was reported which recurred after surgery and roferon treatment. The patient was treated with apatinib at a dose of 500 mg orally, twice daily, 28 days/cycle. The metastatic lesions improved based on computed tomography after apatinib administration in the fourth and eighth month. The progression-free survival of the patient had increased almost to 8 months. The patient showed a good tolerance with only an adverse effect of mild-to-moderate hand-foot syndrome which was managed well. Apatinib is an option for mRCC after previous treatment. However, more and larger trials are still needed.

Keywords: metastatic renal cell carcinoma, apatinib, sunitinib, sorafenib, vascular endothelial growth factor receptor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]